Bausch + Lomb has acquired the rights to a novel platform technology for treating posterior segment diseases of the eye.
Madison, NJ-Bausch + Lomb has acquired the rights to a novel platform technology for treating posterior segment diseases of the eye.
The new addition to the company’s pipeline already has completed the “proof of principle” research phase. If future trials and commercialization are successful, the drug could reduce the need for ongoing pharmacologic intervention for patients with certain diseases, according to the company.
“Through partnership with leading retinal specialists, we hope to advance this innovative new science . . . to preserve vision in patients suffering from posterior segment conditions,” said Cal Roberts, MD, the company’s chief medical officer.
For more articles in this issue of Ophthalmology Times eReport, click here.
